ERBB2 and adenocarcinoma: The phase II DESTINY-Gastric01 trial [1] showed significant effective outcomes of intravenous TDXD compared with standard chemotherapy (physician’s choice of intravenous paclitaxel or irinotecan), improving the overall survival of Asian adults with advanced HER2-positive gastric or GOJ adenocarcinoma who had a history of receiving 2 or more previous therapies.